Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

References for PMC Articles for PubMed (Select 22474202)

1.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS; MRC COIN Trial Investigators.

Lancet Oncol. 2011 Jul;12(7):642-53. doi: 10.1016/S1470-2045(11)70102-4. Epub 2011 Jun 5.

2.

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P.

Ann Oncol. 2011 Jul;22(7):1535-46. doi: 10.1093/annonc/mdq632. Epub 2011 Jan 12.

3.

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4.

4.

Functional roles of multiple feedback loops in extracellular signal-regulated kinase and Wnt signaling pathways that regulate epithelial-mesenchymal transition.

Shin SY, Rath O, Zebisch A, Choo SM, Kolch W, Cho KH.

Cancer Res. 2010 Sep 1;70(17):6715-24. doi: 10.1158/0008-5472.CAN-10-1377. Epub 2010 Aug 24.

5.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.

Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8.

PMID:
20619739
6.

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Bardelli A, Siena S.

J Clin Oncol. 2010 Mar 1;28(7):1254-61. doi: 10.1200/JCO.2009.24.6116. Epub 2010 Jan 25. Review.

PMID:
20100961
7.

Mechanisms of resistance to HER family targeting antibodies.

Kruser TJ, Wheeler DL.

Exp Cell Res. 2010 Apr 15;316(7):1083-100. doi: 10.1016/j.yexcr.2010.01.009. Epub 2010 Jan 11. Review.

PMID:
20064507
8.

Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.

Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG.

Lancet Oncol. 2009 Jul;10(7):709-17. doi: 10.1016/S1470-2045(09)70137-8. Review.

PMID:
19573800
9.

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A.

J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771. Epub 2009 May 18.

10.

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, André T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D.

J Clin Oncol. 2009 Jul 1;27(19):3117-25. doi: 10.1200/JCO.2008.21.6663. Epub 2009 May 18.

11.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P.

N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.

12.

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

Ychou M, Raoul JL, Douillard JY, Gourgou-Bourgade S, Bugat R, Mineur L, Viret F, Becouarn Y, Bouché O, Gamelin E, Ducreux M, Conroy T, Seitz JF, Bedenne L, Kramar A.

Ann Oncol. 2009 Apr;20(4):674-80. doi: 10.1093/annonc/mdn680. Epub 2009 Jan 29.

13.

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience.

Adams RA, Meade AM, Madi A, Fisher D, Kay E, Kenny S, Kaplan RS, Maughan TS.

Br J Cancer. 2009 Jan 27;100(2):251-8. doi: 10.1038/sj.bjc.6604877.

14.

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.

Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P.

J Clin Oncol. 2009 Feb 10;27(5):663-71. doi: 10.1200/JCO.2008.20.8397. Epub 2008 Dec 29.

15.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

16.

Review: Biological relevance of disseminated tumor cells in cancer patients.

Riethdorf S, Wikman H, Pantel K.

Int J Cancer. 2008 Nov 1;123(9):1991-2006. doi: 10.1002/ijc.23825. Review.

PMID:
18712708
17.

Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy.

Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K.

Biochim Biophys Acta. 2008 Dec;1786(2):87-104. doi: 10.1016/j.bbcan.2008.07.002. Epub 2008 Jul 22. Review.

18.

The biological properties of cetuximab.

Vincenzi B, Schiavon G, Silletta M, Santini D, Tonini G.

Crit Rev Oncol Hematol. 2008 Nov;68(2):93-106. doi: 10.1016/j.critrevonc.2008.07.006. Epub 2008 Aug 3. Review.

PMID:
18676156
19.

Epithelial-mesenchymal transition mediated tumourigenesis in the gastrointestinal tract.

Natalwala A, Spychal R, Tselepis C.

World J Gastroenterol. 2008 Jun 28;14(24):3792-7. Review.

20.

Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, Fields AL, Mayer RJ.

J Clin Oncol. 2007 Aug 10;25(23):3456-61.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk